Guidant Clarifies J&J Merger Terms, Incentives For Execs, Antitrust Defense
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug-eluting stent market will prove “sufficiently competitive” for FTC when U.S. pipeline is considered, Guidant CEO Dollens says in justifying the company’s expectation that no material divestitures will result from acquisition by J&J. Guidant exec affirms that preserving “iterative capability” of DES, delivery systems is central to merger plans.
You may also be interested in...
J&J’s Poon Joins Management Triumvirate With Vice Chairman Appointment
Worldwide Chairman-Medicines & Nutritionals Christine Poon joins the Office of the Chairman, which includes CEO Weldon and CFO Darretta. Poon retains management responsibility for the pharmaceutical business.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.